The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA.
Pain Pract. 2010 Sep-Oct;10(5):382-95. doi: 10.1111/j.1533-2500.2009.00344.x.
Chronic pain is a costly and debilitating condition that has proven difficult to treat, solely with medical interventions, due to the complex interplay of biological, psychological, and social factors in its onset and persistence. Many studies have demonstrated the effectiveness of interdisciplinary treatment that includes psychosocial interventions for low back pain. Nevertheless, these interventions continue to be under-utilized due to concerns of cost and applicability. The present study utilized a cost utility analysis to evaluate effectiveness and associated costs of interdisciplinary early intervention for individuals with acute low back pain that was identified as high-risk for becoming chronic. Treatment effectiveness was evaluated using a standard pain measure and quality-adjusted life years, and associated medical and employment costs were gathered for 1 year. Results indicated that subjects improved significantly from pretreatment to 1-year follow-up, and that the early intervention group reported fewer health-care visits and missed workdays than the treatment as usual group. The majority of 1,000 bootstrapped samples demonstrated the dominance of the early intervention program as being both more effective and less costly from a societal perspective. The early intervention treatment was the preferred option in over 85% of samples within an established range of acceptable costs. These results are encouraging evidence for the cost-effectiveness of interdisciplinary intervention and the benefits of targeted early treatment.
慢性疼痛是一种代价高昂且使人虚弱的病症,由于其发病和持续存在涉及到生物、心理和社会因素的复杂相互作用,仅通过医学干预很难治疗。许多研究已经证明了包括心理社会干预在内的多学科治疗对腰痛的有效性。然而,由于对成本和适用性的担忧,这些干预措施仍然未得到充分利用。本研究利用成本效用分析来评估针对被认为有发展为慢性风险的急性腰痛患者的早期多学科干预的有效性和相关成本。使用标准疼痛测量和质量调整生命年来评估治疗效果,并收集了 1 年的相关医疗和就业成本。结果表明,与治疗前相比,受试者在 1 年随访时显著改善,早期干预组报告的医疗就诊次数和旷工天数少于常规治疗组。在 1000 次 bootstrap 抽样的大多数样本中,早期干预方案从社会角度来看既更有效又更节省成本,具有优势。在既定可接受成本范围内,早期干预治疗在超过 85%的样本中是首选方案。这些结果为多学科干预的成本效益和有针对性的早期治疗的益处提供了令人鼓舞的证据。